CSL Licenses Arcturus mRNA Technology, But COVID-19 Vaccine Remains Uncertain
The two companies signed a development and commercialization deal with a $200m upfront payment and milestones of up to $4.3bn.
The two companies signed a development and commercialization deal with a $200m upfront payment and milestones of up to $4.3bn.